MedTrace Logo

Genotype Guided Comparison of Clopidogrel and Prasugrel Outcomes Study

NCT00995514 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 4471

Last updated 2012-05-30

No results posted yet for this study

Summary

The primary objective of this trial is to demonstrate the non-inferiority of clopidogrel compared to prasugrel over 6 months in cardiovascular disease patients when the clopidogrel cohort is limited to the estimated 70% of the population that are CYP2C19 extensive metabolizers. This protocol will examine the comparative effectiveness of these two strategies.

Conditions

Sponsors & Collaborators

  • Medco Health Solutions, Inc.

    lead INDUSTRY

Principal Investigators

  • Eric J Stanek, Pharm.D. · Medco Health Solutions, Inc.

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-10-31
Primary Completion
2012-05-31
Completion
2012-05-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00995514 on ClinicalTrials.gov